Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2008 1
2011 1
2012 3
2013 3
2014 4
2015 1
2016 2
2017 3
2018 4
2019 5
2020 10
2021 9
2022 8
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis.
Nomura S, Watanabe T, Honma R, Matsukura S, Ito E, Imai JI, Kiko Y, Suzuki O, Hashimoto Y, Kojima M, Furukawa S, Soeda S, Watanabe S, Fujimori K. Nomura S, et al. Among authors: soeda s. Fukushima J Med Sci. 2024 Apr 26;70(2):65-73. doi: 10.5387/fms.23-00011. Epub 2024 Mar 15. Fukushima J Med Sci. 2024. PMID: 38494731 Free article.
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual Treatment Report for 2015.
Yoshino K, Kurita T, Takahashi F, Nagase S; Board members of the 2022 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Yoshino K, et al. J Obstet Gynaecol Res. 2023 Nov;49(11):2584-2592. doi: 10.1111/jog.15767. Epub 2023 Aug 21. J Obstet Gynaecol Res. 2023. PMID: 37602964
SPON1 is an independent prognostic biomarker for ovarian cancer.
Miyakawa R, Kobayashi M, Sugimoto K, Endo Y, Kojima M, Kobayashi Y, Furukawa S, Honda T, Watanabe T, Asano S, Soeda S, Hashimoto Y, Fujimori K, Chiba H. Miyakawa R, et al. Among authors: soeda s. J Ovarian Res. 2023 May 13;16(1):95. doi: 10.1186/s13048-023-01180-8. J Ovarian Res. 2023. PMID: 37179355 Free PMC article.
Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report.
Kojima M, Soeda S, Okabe C, Sato T, Kamo N, Ueda M, Endo Y, Nomura S, Tokuda E, Furukawa S, Kataoka M, Fujita S, Saji S, Watanabe T, Fujimori K. Kojima M, et al. Among authors: soeda s. Fukushima J Med Sci. 2022 Dec 21;68(3):191-195. doi: 10.5387/fms.2022-10. Epub 2022 Nov 9. Fukushima J Med Sci. 2022. PMID: 36351631 Free PMC article.
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y. Shoji T, et al. Among authors: soeda s. Int J Clin Oncol. 2022 Dec;27(12):1874-1880. doi: 10.1007/s10147-022-02246-1. Epub 2022 Oct 10. Int J Clin Oncol. 2022. PMID: 36214925
Claudin‑9 is a novel prognostic biomarker for endometrial cancer.
Endo Y, Sugimoto K, Kobayashi M, Kobayashi Y, Kojima M, Furukawa S, Soeda S, Watanabe T, Higashi AY, Higashi T, Hashimoto Y, Fujimori K, Chiba H. Endo Y, et al. Among authors: soeda s. Int J Oncol. 2022 Nov;61(5):135. doi: 10.3892/ijo.2022.5425. Epub 2022 Sep 21. Int J Oncol. 2022. PMID: 36129146 Free PMC article.
55 results